Last reviewed · How we verify

NCT05679609

Incentive Spirometry in Routine Management of COPD Patients

Completed NA Last updated 11 January 2023
What this trial tests

NA trial testing incentive spirometry in COPD in 40 participants. Completed in 1 July 2022.

Timeline
1 March 2021
Primary endpoint
1 May 2022
1 July 2022

Quick facts

Lead sponsorMenoufia University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment40
Start date1 March 2021
Primary completion1 May 2022
Estimated completion1 July 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Menoufia University

Who can join

40 and older, any sex, with COPD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The incentive spirometer is a device that encourages patients, with visual and other positive feedback, to maximally inflate their lungs and sustain that inflation. However, its efficacy in patients with COPD has been little documented especially in diaphragmatic function. This study tried to assess the role of incentive spirometry on Spirometric functions, Sonographic diaphragmatic function, and the scale of dyspnea in COPD patients with exacerbation and with follow-up of these parameters after 2 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of incentive spirometry

Trials testing the same drug.

Other recruiting trials for COPD

Currently open trials in the same condition.

Other Menoufia University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05679609.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing